FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • January 12th, 2006 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO THE LICENSE AGREEMENT (this “First Amendment”), effective as of December 30th, 2005 (the “First Amendment Effective Date”), is entered into by and between the University of Connecticut Health Center (“UCHC”), a public institution of higher education, c/o its Center for Science and Technology Commercialization, with a principal office at 263 Farmington Avenue, Farmington, CT 06030-6207, and Halozyme, Inc. (“HALOZYME”), a California Corporation, with a principal place of business at 11588 Sorrento Valley Road, Suite 17, San Diego, CA 92121, and is the first amendment to that LICENSE AGREEMENT (the “License Agreement”) between UCHC and Deliatroph Pharmaceuticals, Inc. (the predecessor-in-interest of HALOZYME) that was entered into as of November 15, 2002. Each of UCHC and HALOZYME are sometimes referred to herein as a party, collectively as the parties.
